Brief: Medicenna Announces Single-Agent Response And Durability Of MDNA11 In Phase 1/2 Ability Study During Dose Escalation
06/11/2023 12:08
Nov 6 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES PROMISING SINGLE-AGENT RESPONSE AND
DURABILITY OF MDNA11 IN THE PHASE 1/2 ABILITY STUDY DURING DOSE
ESCALATION AT THE 38TH ANNUAL MEETING OF THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER (SITC)
* MEDICENNA THERAPEUTICS- MDNA11 IS GENERALLY WELL TOLERATED
Source text for Eikon: ID:nGNX4Vwx6k
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results